Flerie

Adoption of the profit and loss statements and balance sheets, disposal of profits, and resolution regarding discharge of liability
The annual general meeting resolved to adopt the profit and loss statement and balance sheet and the group’s profit and loss statement and balance sheet for the financial year of 2023.

The annual general meeting resolved, in accordance with the board of directors’ proposal, that the company’s accumulated profits shall be carried forward in new account and that no dividend shall be paid for the financial year 2023.

The annual general meeting resolved to grant discharge of liability for the members of the board of directors and the managing director for the financial year of 2023.

Board of directors, auditors, and fees
The annual general meeting resolved that the board of directors shall consist of four ordinary members without deputies. Furthermore, the annual general meeting resolved to re-elect Wenche Rolfsen, Uli Hacksell and Lennart Hansson as board members, to elect Karl Tobieson as a new board member, and to re-elect Wenche Rolfsen as chairman of the board of directors. The annual general meeting resolved that a registered accounting firm shall be elected as auditor and to the re-elect the auditing company PricewaterhouseCoopers (PwC) as the company’s auditor, with the authorized public accountant Magnus Lagerberg as the auditor in charge. The annual general meeting further resolved to appoint Ernst & Young AB and KPMG AB as special auditors with the right to individually review the board of directors' report in connection with new share issues with provisions on payment in kind or in cases where shares are to be subscribed for with set-off rights.

The annual general meeting resolved that the fees for the board of directors for the time until the end of the next annual general meeting shall amount to SEK 500,000 for the chairman of the board of directors and SEK 235,000 for each ordinary member of the board of directors not employed by the company, or, where applicable, to a reduced amount in proportion to the number of months of service. Karl Tobieson waives his right to renumeration. Fees to the company’s auditors for the same period shall be paid in accordance with approved invoices.

For more information:
Jenny Sundqvist, CEO
Phone: +46 8 122 038 50
E-Mail: jenny.sundqvist@indexpharma.com

Johan Giléus, CFO and Deputy CEO
Phone: +46 8 122 038 50
E-mail: johan.gileus@indexpharma.com

Publication
The information was submitted for publication through the agency of the contact person set out above at 18:30 CET on 7 May 2024.

InDex Pharmaceuticals in brief
InDex Pharmaceuticals has a vision to help patients with immunological diseases where there is a high unmet medical need. Cobitolimod was being evaluated in the phase III program CONCLUDE for moderate to severe left-sided ulcerative colitis – a debilitating, chronic inflammation of the large intestine.

InDex Pharmaceuticals is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com.

This is an English translation of the Swedish press release. In case of discrepancies between the English translation and the Swedish press release, the Swedish press release shall prevail. Information in this press release is intended for investors.